Automate Your Wheel Strategy on PTCT
With Tiblio's Option Bot, you can configure your own wheel strategy including PTCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PTCT
- Rev/Share 22.694
- Book/Share -2.378
- PB -18.8141
- Debt/Equity -2.0974
- CurrentRatio 3.8906
- ROIC 0.3166
- MktCap 3545958180.0
- FreeCF/Share 9.5274
- PFCF 4.7645
- PE 5.8753
- Debt/Assets 0.1467
- DivYield 0
- ROE -0.717
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PTCT | Truist | -- | Buy | -- | $80 | June 17, 2025 |
| Upgrade | PTCT | BofA Securities | Neutral | Buy | -- | $68 | May 9, 2025 |
| Upgrade | PTCT | Citigroup | Sell | Neutral | -- | $40 | May 7, 2025 |
| Upgrade | PTCT | BofA Securities | Underperform | Neutral | $41 | $55 | March 11, 2025 |
| Initiation | PTCT | Scotiabank | -- | Sector Perform | -- | $55 | March 7, 2025 |
| Upgrade | PTCT | Morgan Stanley | Equal Weight | Overweight | $45 | $67 | Dec. 13, 2024 |
| Upgrade | PTCT | RBC Capital Mkts | Sector Perform | Outperform | $39 | $63 | Dec. 3, 2024 |
| Resumed | PTCT | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
| Resumed | PTCT | UBS | -- | Buy | -- | $47 | Aug. 26, 2024 |
News
Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Investors to Inquire about Securities Investigation
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC Therapeutics, Inc. (PTCT)
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q1 2025 Earnings Call May 6, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Judah Frommer - Morgan Stanley Geoff Meacham - Citigroup Tazeen Ahmad - Bank of America Han Hu - Barclays Peyton Bohnsack - TD Cowen Operator Ladies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics First Quarter 2025 Earnings Conference Call.
Read More
An Investigation Has Commenced on Behalf of PTC Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PTCT Losses
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Lost Money on PTC Therapeutics, Inc. (PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announcing results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Reach Out
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral
- Label includes full spectrum of PKU patients - - European launch preparations underway - WARREN, N.J. , April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the marketing authorization application for Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU).
Read More
PTC Therapeutics says European Commission will remove muscle disorder drug
Published: March 28, 2025 by: Reuters
Sentiment: Negative
PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug in January.
Read More
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
Published: March 28, 2025 by: PRNewsWire
Sentiment: Neutral
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy.
Read More
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
— Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% — — Genetic variant analysis of Phase 3 APHENITY trial demonstrates meaningful effect in classical subjects with non-BH4 responsive genotypes — WARREN, N.J. , March 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
Read More
PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head of IR Matthew Klein - CEO Eric Pauwels - Chief Business Officer Pierre Gravier - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Tiago Fauth - Wells Fargo Eli Merle - UBS Gena Wang - Barclays Joel Beatty - Baird Sami Corwin - William Blair Peyton Bohnsack - TD Cowen Tazeen Ahmad - Bank of America Securities David Lebowitz - Citi Operator Ladies and gentlemen, thank you for standing …
Read More
PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
– Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing – – License and collaboration agreement with Novartis for PTC518 Huntington's disease program closed in January 2025 – – Cash of over $2.0 billion as of January 2025 – WARREN, N.J. , Feb. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024.
Read More
PTC Therapeutics to Participate in Upcoming Investor Conferences
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
WARREN, N.J. , Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care 2025 Conference Tuesday, March 4 at 11:10 a.m.
Read More
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral
- PDUFA target action date of Aug. 19, 2025 - WARREN, N.J. , Feb. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA).
Read More
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
WARREN, N.J. , Feb. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27, at 4:30 p.m.
Read More
About PTC Therapeutics, Inc. (PTCT)
- IPO Date 2013-06-20
- Website https://www.ptcbio.com
- Industry Biotechnology
- CEO Matthew B. Klein F.A.C.S.,
- Employees 939